F&V Capital Management LLC Purchases Shares of 176,995 AxoGen, Inc. $AXGN

F&V Capital Management LLC purchased a new position in shares of AxoGen, Inc. (NASDAQ:AXGN) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 176,995 shares of the medical equipment provider’s stock, valued at approximately $5,793,000. AxoGen makes up about 0.9% of F&V Capital Management LLC’s portfolio, making the stock its 29th biggest holding. F&V Capital Management LLC owned 0.38% of AxoGen at the end of the most recent quarter.

A number of other institutional investors also recently made changes to their positions in the business. Allspring Global Investments Holdings LLC bought a new position in shares of AxoGen during the 4th quarter valued at $800,000. SG Americas Securities LLC lifted its stake in AxoGen by 459.9% in the fourth quarter. SG Americas Securities LLC now owns 65,480 shares of the medical equipment provider’s stock worth $2,143,000 after purchasing an additional 53,786 shares during the last quarter. Assenagon Asset Management S.A. lifted its stake in AxoGen by 7.0% in the fourth quarter. Assenagon Asset Management S.A. now owns 1,379,849 shares of the medical equipment provider’s stock worth $45,162,000 after purchasing an additional 90,777 shares during the last quarter. FNY Investment Advisers LLC purchased a new stake in AxoGen during the third quarter valued at about $64,000. Finally, Jacobs Levy Equity Management Inc. boosted its position in AxoGen by 23.3% during the third quarter. Jacobs Levy Equity Management Inc. now owns 241,592 shares of the medical equipment provider’s stock valued at $4,310,000 after buying an additional 45,592 shares during the period. Hedge funds and other institutional investors own 80.29% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have recently commented on AXGN shares. Citigroup reiterated an “outperform” rating on shares of AxoGen in a report on Tuesday, February 24th. Wall Street Zen cut AxoGen from a “strong-buy” rating to a “buy” rating in a report on Saturday, February 28th. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $40.00 price target on shares of AxoGen in a research note on Monday. HC Wainwright boosted their price objective on AxoGen from $26.00 to $39.00 and gave the company a “buy” rating in a research report on Friday, December 5th. Finally, Raymond James Financial reissued an “outperform” rating and set a $41.00 price objective on shares of AxoGen in a research note on Monday, February 23rd. Nine investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $39.75.

Insider Activity

In related news, insider Erick Wayne Devinney sold 5,221 shares of the company’s stock in a transaction that occurred on Monday, March 16th. The stock was sold at an average price of $32.84, for a total transaction of $171,457.64. Following the completion of the transaction, the insider owned 262,781 shares in the company, valued at $8,629,728.04. This represents a 1.95% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 2.78% of the company’s stock.

AxoGen Stock Performance

AxoGen stock opened at $33.58 on Thursday. The company has a current ratio of 5.11, a quick ratio of 3.31 and a debt-to-equity ratio of 0.51. The firm has a market cap of $1.74 billion, a P/E ratio of -98.76 and a beta of 0.98. AxoGen, Inc. has a 1-year low of $9.22 and a 1-year high of $36.00. The firm has a 50-day moving average of $32.72 and a 200-day moving average of $27.65.

AxoGen (NASDAQ:AXGN) last announced its quarterly earnings results on Tuesday, February 24th. The medical equipment provider reported $0.07 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.08 by ($0.01). AxoGen had a negative net margin of 6.97% and a negative return on equity of 13.44%. The business had revenue of $59.90 million for the quarter, compared to analysts’ expectations of $59.90 million. Sell-side analysts expect that AxoGen, Inc. will post -0.29 EPS for the current year.

AxoGen Profile

AxoGen, Inc is a Florida-based medical technology company that develops and commercializes surgical solutions for peripheral nerve damage. Founded in 2002 and headquartered in Alachua, Florida, the company focuses on restoring nerve function and improving patient outcomes through innovative biologic and engineered products. AxoGen’s offerings address a range of traumatic and iatrogenic injuries, offering alternatives to traditional nerve autografts.

The company’s core product portfolio includes the Avance® Nerve Graft, a decellularized human nerve allograft designed to bridge nerve gaps without the need for a secondary harvest site, and the Axoguard® Nerve Connector and Protector devices, which facilitate nerve coaptation and protect repaired sites from surrounding scar tissue.